| Dr Nikolai Klebanov, MD | |
|
41 Mall Road, Burlington, MA 01805-3308 | |
| (781) 744-8000 | |
| Not Available |
| Full Name | Dr Nikolai Klebanov |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 41 Mall Road, Burlington, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386202158 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 280386 (Massachusetts) | Secondary |
| 207N00000X | Dermatology | 1014901 (Massachusetts) | Primary |
| Entity Name | Lahey Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538194980 PECOS PAC ID: 2264336528 Enrollment ID: O20031120000097 |
News Archive
On March 1, 2012, the American Academy of Otolaryngology-Head and Neck Surgery Foundation published a new Clinical Practice Guideline on Sudden Hearing Loss (SHL). This guideline is published as a supplement to Otolaryngology-Head and Neck Surgery.
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa's president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw's 11th Annual Healthcare Conference.
NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.
Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen's DAC Blockers Platform and reviewed disease model data for selected product candidates.
› Verified 2 days ago
| Entity Name | Lahey Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063447316 PECOS PAC ID: 2264336528 Enrollment ID: O20040629001269 |
News Archive
On March 1, 2012, the American Academy of Otolaryngology-Head and Neck Surgery Foundation published a new Clinical Practice Guideline on Sudden Hearing Loss (SHL). This guideline is published as a supplement to Otolaryngology-Head and Neck Surgery.
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa's president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw's 11th Annual Healthcare Conference.
NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.
Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen's DAC Blockers Platform and reviewed disease model data for selected product candidates.
› Verified 2 days ago
| Entity Name | Beth Israel Lahey Health Primary Care, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063873842 PECOS PAC ID: 7719291434 Enrollment ID: O20160517000441 |
News Archive
On March 1, 2012, the American Academy of Otolaryngology-Head and Neck Surgery Foundation published a new Clinical Practice Guideline on Sudden Hearing Loss (SHL). This guideline is published as a supplement to Otolaryngology-Head and Neck Surgery.
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa's president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw's 11th Annual Healthcare Conference.
NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.
Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen's DAC Blockers Platform and reviewed disease model data for selected product candidates.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nikolai Klebanov, MD 680 Centre St, Brockton, MA 02302-3308 Ph: (508) 941-7000 | Dr Nikolai Klebanov, MD 41 Mall Road, Burlington, MA 01805-3308 Ph: (781) 744-8000 |
News Archive
On March 1, 2012, the American Academy of Otolaryngology-Head and Neck Surgery Foundation published a new Clinical Practice Guideline on Sudden Hearing Loss (SHL). This guideline is published as a supplement to Otolaryngology-Head and Neck Surgery.
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa's president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw's 11th Annual Healthcare Conference.
NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.
Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen's DAC Blockers Platform and reviewed disease model data for selected product candidates.
› Verified 2 days ago
Pauline B Reohr, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: Lahey Clinic, 41 Mall Rd., Burlington, MA 01805 Phone: 781-744-8457 Fax: 781-744-5687 | |
Dr. Adele Ann Moreland, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: Lahey Cinic Inc, 41 Mall Road, Burlington, MA 01805 Phone: 781-744-8000 | |
Dr. Siobhan M Mannion, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 20 Wall St, Burlington, MA 01805 Phone: 781-744-8000 Fax: 978-538-4820 | |
Dr. Katherine S. Masterpol, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 83 Cambridge St Ste 1a, Burlington, MA 01803 Phone: 781-272-7022 Fax: 781-272-8786 | |
Dr. Adam Daniel Lipworth, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 67 S. Bedford Street, Lahey Hospital & Medical Center, Burlington, MA 01803 Phone: 781-744-5115 Fax: 781-744-5687 | |
Dr. Adam Jared Wulkan, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 67 S. Bedford Street, Burlington, MA 01803 Phone: 781-744-5115 Fax: 781-744-5687 | |
Zachary A Schwager, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: Lahey Hospital And Medical Center, 67 S. Bedford Street - Dermatology Department, Burlington, MA 01803 Phone: 781-744-5115 Fax: 781-744-5687 |